Biomea Fusion, Inc.
BMEAHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Biomea Fusion, Inc. (BMEA) is listed under Biotechnology. The company carries a $43.5M market cap, placing it firmly in the micro-cap category. It's lead clinical program's drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes.
Market Cap
$43.5M
Beta
-0.30
P/E (TTM)
—
P/E (Fwd)
-0.64
EPS (TTM)
$-0.29
EPS (Fwd)
$-0.94
ROE
-164.1%
ROA
-63.5%
Cash
$34.8M
Total Debt
$877,000
Free CF
-$27.8M
52W Change
-57.8%
Annual Financials
Cash vs Debt
Where BMEA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, BMEA finished 41.26% below its 150-day moving average ($1.43) and 40.43% below its 200-day moving average ($1.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BMEA overbought or oversold?
At the October 20, 2026 close, BMEA's RSI(14) was 29.5, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $34.8M in cash and $877K in debt, BMEA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$27.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -164.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The relatively low beta of -0.30 suggests BMEA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, BMEA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Biomea Fusion, Inc.'s trajectory.